SCHEMBL8378633

SCHEMBL8378633

CC(C)C[C@@H]([C@H](O)CCl)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ADRA2B P18089 2/20 0.40
ADRA2C P18825 2/20 0.40
SLC6A2 P23975 2/20 0.40
HTR2A P28223 2/20 0.40
ADRA1A P35348 2/20 0.40
SLC6A3 Q01959 2/20 0.40
KCNH2 Q12809 2/20 0.40
SLC22A2 O15244 1/20 0.40
SLC22A1 O15245 1/20 0.40
SLC22A3 O75751 1/20 0.40
ESR1 P03372 1/20 0.40
CHRM2 P08172 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8378631 1.00 TSHR (0.40) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL9709386 0.84 TRPA1 (0.39) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL5168408 0.82 SIGMAR1 (0.41) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL5169753 0.82 SIGMAR1 (0.41) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL5171350 0.82 SIGMAR1 (0.41) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL5171075 0.82 SIGMAR1 (0.41) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
Hydrochloric Acid SCHEMBL5170563 0.81 SIGMAR1 (0.40) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL7456355 0.81 SIGMAR1 (0.40) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
Hydrochloric Acid SCHEMBL5169015 0.81 SIGMAR1 (0.40) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL8950842 0.80 TSHR (0.44) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0796239-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (S,S) AMINOEPOXIDES, KEY INTERMEDIATES FOR HIV PROTEASE INHIBITORS, VIA THEIR CHLOROHYDRINES BOEHRINGER INGELHEIM CA LTD (CA) 1999-03-31 EP disclosed
US-5550291-A Process for key intermediates for HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) 1996-08-27 US disclosed